| Latest Forum Topics / Biosensors |
 Post Reply
|
|
Is Biosensors a good buy?
|
|||||||
|
calculus1985
Senior |
19-Aug-2010 18:32
Yells: "lollymotion dot com" |
||||||
|
x 0
x 0 Alert Admin |
it break the resistance!!!! HIGH is 0.84!!! closing at 0.835! Bullish Signal detected!!! a Bullish uptrend might follow??? |
||||||
| Useful To Me Not Useful To Me | |||||||
|
gbleng
Member |
19-Aug-2010 11:59
|
||||||
|
x 0
x 0 Alert Admin |
Will it break the 0.825 resistance level today? | ||||||
| Useful To Me Not Useful To Me | |||||||
|
|
|||||||
|
lowchia
Veteran |
18-Aug-2010 22:49
|
||||||
|
x 0
x 0 Alert Admin |
On Wednesday, Biosensor gap up from the support at $0.795 and closed at $0.81 with HIGH volume of 6.56 million shares traded. A doji star occurred (where a doji gaps above or below the previous candle). This often signals a reversal with confirmation occurring on the next bar. Both RSI & MACD are turning bullish as MACD about to perform a “golden cross” Important Resistance of Biosensor: $0.825 Immediate Support of Biosensor: $0.795 Currently prices are supported by the technical / 50/100/200 days MA at $0.795 As seen from the charts, Biosensor has been forming an bullish pattern “ascending triangle” since Mar10. Any breakout above $0.825 will be considered a bullish signal for Biosensors. SEE ANALYSIS FOR COSCO We would advise investors to keep a look out if the major resistance at $0.825 can be broken at high volume for buying opportunities. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
allright
Senior |
18-Aug-2010 08:58
|
||||||
|
x 0
x 0 Alert Admin |
sorry about the d earlier post repeating 3 times ...must have been too happy hehe. From DJ news DJ MARKET TALK: Biosensors May Gain; Gets
Nod To Sell In Taiwan (2010/08/18 08:56AM)
|
||||||
| Useful To Me Not Useful To Me | |||||||
|
allright
Senior |
18-Aug-2010 08:55
|
||||||
|
x 0
x 0 Alert Admin |
NEWS RELEASE BioMatrix™ Drug Eluting Stent System Approved for Sale in Taiwan Singapore, 18 August 2010 – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP) today announced that it had received approval for its BioMatrix™ drug-eluting stent system from the Department of Health in Taiwan. “We are delighted to have obtained regulatory approval for sale of BioMatrix in Taiwan, an important regional market with a high rate of coronary stent usage,” said Jeffrey B. Jump, President and CEO of Biosensors. “This is further confirmation of the proven safety and efficacy of our products, and reflects our ongoing commitment to expanding treatment options for physicians and improving quality of life for patients.” The BioMatrix drug-eluting stent system received CE Mark approval in January 2008 and is currently commercially available in more than 70 markets around the world. ### Media and Investor Relations Contact Biosensors International Group Mr. Loh Chee Mun Senior Vice President Tel: (65) 6213 5708 Email: cm.loh@biosensors.com Media Relations / Investor Relations Firm United States Allen & Caron Inc. Mr. Matt Clawson Executive Vice President, Investor Relations Tel: (1) 949 474 4300 Email: matt@allencaron.comNEWS RELEASE BioMatrix™ Drug Eluting Stent System Approved for Sale in Taiwan Singapore, 18 August 2010 – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP) today announced that it had received approval for its BioMatrix™ drug-eluting stent system from the Department of Health in Taiwan. “We are delighted to have obtained regulatory approval for sale of BioMatrix in Taiwan, an important regional market with a high rate of coronary stent usage,” said Jeffrey B. Jump, President and CEO of Biosensors. “This is further confirmation of the proven safety and efficacy of our products, and reflects our ongoing commitment to expanding treatment options for physicians and improving quality of life for patients.” The BioMatrix drug-eluting stent system received CE Mark approval in January 2008 and is currently commercially available in more than 70 markets around the world. ### Media and Investor Relations Contact Biosensors International Group Mr. Loh Chee Mun Senior Vice President Tel: (65) 6213 5708 Email: cm.loh@biosensors.com Media Relations / Investor Relations Firm United States Allen & Caron Inc. Mr. Matt Clawson Executive Vice President, Investor Relations Tel: (1) 949 474 4300 Email: matt@allencaron.comNEWS RELEASE BioMatrix™ Drug Eluting Stent System Approved for Sale in Taiwan Singapore, 18 August 2010 – Biosensors International Group, Ltd. (“Biosensors”, “Company”, Bloomberg: BIG SP) today announced that it had received approval for its BioMatrix™ drug-eluting stent system from the Department of Health in Taiwan. “We are delighted to have obtained regulatory approval for sale of BioMatrix in Taiwan, an important regional market with a high rate of coronary stent usage,” said Jeffrey B. Jump, President and CEO of Biosensors. “This is further confirmation of the proven safety and efficacy of our products, and reflects our ongoing commitment to expanding treatment options for physicians and improving quality of life for patients.” The BioMatrix drug-eluting stent system received CE Mark approval in January 2008 and is currently commercially available in more than 70 markets around the world. ### Media and Investor Relations Contact Biosensors International Group Mr. Loh Chee Mun Senior Vice President Tel: (65) 6213 5708 Email: cm.loh@biosensors.com Media Relations / Investor Relations Firm United States Allen & Caron Inc. Mr. Matt Clawson Executive Vice President, Investor Relations Tel: (1) 949 474 4300 Email: matt@allencaron.com
|
||||||
| Useful To Me Not Useful To Me | |||||||
|
|
|||||||
|
lostbell
Member |
18-Aug-2010 08:24
Yells: "GOD BLESS EVERYONE!!!" |
||||||
|
x 0
x 0 Alert Admin |
BioMatrix™ Drug Eluting Stent System Approved for Sale in Taiwan | ||||||
| Useful To Me Not Useful To Me | |||||||
|
topdog22
Senior |
03-Aug-2010 21:41
|
||||||
|
x 0
x 0 Alert Admin |
Well, at least the new president Jump likes to talk to the press. Perhaps this will keep the company's name front and center. Maybe someone will concentrate on the Asia focused Mutual funds! I think there are over 200 based in the US that invest in companies located here, China, Korea, Malaysia, India, Indonesia, Japan etc. Plus all the mutual funds that specialize in eastern europe. =DJ INTERVIEW: Biosensors CEO: Looking To Develop Non-Coronary Stent Business (2010/08/03 16:27PM) By Sam Holmes Of DOW JONES NEWSWIRES SINGAPORE (Dow Jones)--Singapore biomedical manufacturer Biosensors International Group Ltd. (B20.SG) Chief Executive Jeffrey Jump said the company is now looking to develop products using its stent technology for applications outside the heart. The company last month acquired some of the assets of California-based CardioMind Inc., which makes stents that are 70% smaller than those commonly available, a move that Jump hopes will allow Biosensors to develop drug-eluting stent products--man-made tubes designed to support arteries--for use in smaller vessels throughout the body such as those in the brain and peripheral arteries. "Right now we''re only focused on coronaries but this will work on peripheral, for example below the knee or foot," Jump told Dow Jones Newswires in an interview. "(Neurology is) where cardiology was 15 years ago so it allows us to be at the forefront of this new market technology." Biosensors'' results for the first quarter ended June 30 announced earlier last week showed a net profit of US$3.2 million, down 23% from a year earlier, reflecting the US$6.0 million charge taken for the closure of its U.S. operations. The weaker euro this year has also affected its revenue, much of which is derived from European markets and exchanged into U.S. dollars. However, Jump said that despite the currency volatility, the company maintains its revenue guidance of US$135 million to US$145 million for the 2011 financial year. Biosensors reported revenue of US$33.0 million for its fiscal first quarter. Jump also said "there are discussions that go on all the time" with other companies in relation to merger opportunities but that Biosensors isn''t looking to make itself an acquisition target for larger drug-eluting stent producers. The drug-eluting stent business is dominated by four large U.S. biomedical groups: Abbott Laboratories, Johnson & Johnson (JNJ), Boston Scientific Corp. (BSX), Abbott Laboratories (ABT) and Medtronic Inc. (MDT). "If somebody wanted to step in and offer a premium, that can always happen but that''s not how we''re running the company," he said. "I think we probably are continuing to be annoying to at least three of the big four." -By Sam Holmes, Dow Jones Newswires; +65-6415-4157; samuel.holmes@dowjones.com |
||||||
| Useful To Me Not Useful To Me | |||||||
|
lowchia
Veteran |
31-Jul-2010 20:39
|
||||||
|
x 0
x 0 Alert Admin |
On Friday, Biosensor continues to trend inside the channel region and closed at $0.815 with moderate volume of 5.43 million shares traded. A short black candle sticks with no upper/lower shadow indicates low interest from the investors. Both RSI & MACD are bearish as MACD perform a “cross down” on Friday. Important Resistance of Biosensor: $0.83 Immediate Support of Biosensor: $0.795 Currently prices are supported by the technical /20 days MA at $0.795. It is clear that Biosensor has problem breaking the major resistance at $0.83 despite 3 solid attempts at April/May/July 2010 respectively. SEE ANALYSIS FOR OLAM Although Biosensor seems to be forming a symmetrical triangle with “higher high” and “higher low” but we do not advise to enter till $0.83 resistance can be broken at high volume. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
|
|||||||
|
junction
Senior |
31-Jul-2010 13:38
|
||||||
|
x 0
x 0 Alert Admin |
What I don't understand is why the management decided to sell bonds to some private (privileged) investors at an extremely high discount of 9%+ Plus warrants exchangeable for shares thrown in. Why not burrow from banks at very much lower interest. why not give the shareholders a chance to buy the bonds? Any kelong here? | ||||||
| Useful To Me Not Useful To Me | |||||||
|
investor
Senior |
31-Jul-2010 13:37
|
||||||
|
x 0
x 0 Alert Admin |
I think that it is a matter of time before more institutions become interested in Biosensors. (Provided everything goes according to their future projections and plans). Why ? Biosensors only became profitable in FY 2010 end Mar. At the last Q1 2011 conference, there were several new stockbroking firm analysts present, namely DBS Vickers, Lim & Tan, Kim Eng and even UBS (who previously used to cover Biosensors but had drop coverage). The new analysts will take time to be acquainted with Biosensors' business (They need to differentiate MACE, TLR, Late loss, etc, patent etc.) Even if Terumo is not interested in Biosensors, - It does not matter. WHat matters is that they are at the mercy of the licensing business. They paid US$40m upfront to negotiate reduction in royalties for a 5 yr period, and there is left only 2 1/2 yrs. Their aggressiveness in the big clinical trials in Europe and the coming approval in Japan shows that this is a profit spinner for them and Biosensors. They paid US$3.6m in royalties in Q1 and assuming that this is 25 % of their revenue, that means their revenue is US$14.4m. As gross margins are high (Biosensors gross margin is probably above 80 %), profit attributable to them should be OK. If you look at total sales, based on current Q1 results, Biosensors generate US$17.6m, Terumo generate US$14.4m (estimates) and JWMS generate US$23m (of which 11.5m belongs to Biosensors, then total DES sales for Q1 is US$43.5m, annualising it, you get US$174m - an impressive figure for a new startup. Biosensors is predicting that their own DES sales will increase 40 % this yr, and I am sure that Terumo, JWMS will also generate increase in sales. (Note we are not including future sales from Japan) GOing forward, if things panned out - no reason not to expect more interest in Biosensors. Above are conjectures only - may not necessary turn out to be true. Not a call to buy/sell. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
topdog22
Senior |
31-Jul-2010 01:57
|
||||||
|
x 0
x 0 Alert Admin |
I agree with Senior's points. However Terumo does not have a history of making acquisitions at reasonable prices, they are bargain hunters. I believe the most they paid for a company was under a $ billion; and that deal had a very strong "earn-out" component. Biosenors is controlled by a few major shareholders and they do not seem interested in bargain prices. What truly puzzles me is that BIG has very few institutional investors. Why hasn't the company retained a "sell side" firm to help it raise visibility with all the mutual funds aimed at Asia? BIG is a serious contender in all these fast growth markets. Just don't get it. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
investor
Senior |
30-Jul-2010 22:07
|
||||||
|
x 0
x 0 Alert Admin |
Apologies - The projected revenue from Japan for Terumo should be US$120m, assuming they have a 20 % share of the mkt. (Japan's mkt is approx US$600m). |
||||||
| Useful To Me Not Useful To Me | |||||||
|
|
|||||||
|
investor
Senior |
30-Jul-2010 22:04
|
||||||
|
x 0
x 0 Alert Admin |
Nomura held a post results lunch meeting with the CEO of Biosensors. Key points from the meeting : 1) The CEO believes that the China mkt will be as big as US (ie US$2 billion) by 2015. (And JWMS is the no 3 player in China right now) 2) Acquisition of Cardiomind reflects new strategy to expand product line, of which there will be more of such acquisitions. 3) Biofreedom will be their important Trump Card - It will reduce the need to have dual antiplatet drug therapy, and CEO believes that this product will have a good chance of making a difference in the US mkt. 4) Royalties from Terumo reflects Terumo's success in Europe, Asia, Latin AMerica and the mgmt is looking forward to the approval of Nobori in Japan to drive a new source of revenue. My own thinking on Terumo - They are aggressive in conducting major clinical trials in Europe. Their license from Biosensors is for a period of 5 year (of which I believe 2 and 1/2 yrs have passed !). I believe that when they get approval in Japan and if they get a 20 % or more mkt share, this will translate to a revenue of US$200m, coupled with revenue from Europe, then they will start worrying, as they cannot control what will happen, when the license expires. Also, Biosensors is rapidly coming out with new products - Biomatrix flex, Biofreedom, Cardiomind - what is the impact to them ? Some superficial conjectures. - Not a call to buy/sell. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
topdog22
Senior |
30-Jul-2010 21:41
|
||||||
|
x 0
x 0 Alert Admin |
It is regrettable that TERUMO is such a timid organization. It seems that if TERUMO acquired BIG it could quickly become a leader in the INTERVENTIONAL space in CHINA and other fast growing areas of the word, while lsimultaneously broadening their interventional line with the addition of BIG's small stent and new drug delivery technology. IT could also provide access to DEVAX's new untapped market. Too bad they do not seem to grasp the big picture. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
swissvic
Member |
30-Jul-2010 14:55
|
||||||
|
x 0
x 0 Alert Admin |
Event. According to its press release dated July 29 2010,
Devax Inc announced that the company has recevied CE Mark for its AXXESS Biolimus A9 Eluting Bifurcation Stent System, allowing the company to initiate sales in the EU and other CE markets (mainly Asia ex-Japan,
Under a licensing agreement dated December 2003, Biosensors is entitled to:
i) receive royalties, including an annual minimum royalty, based on an undisclosed percentage of AXXESS revenue and
ii) provide stent-coating services to Devax at a premium above cost.
the potential market size is esimated to be US$1.3bn worldwide.
Based on our preliminary research, AXXESS is one of the few pioneers in this technology with a CE mark, and none of the Big Fours has been successful in commercializing a similar product so far.
Therefore we think there are more possibilities to this partnership, which could potentially involve a distributorship.
In this regard, we believe Biosensors would be able to provide speed-to-market by sharing its knowledge base on reiumbursement approval process in key markets such as . While the cashflow potential is unlikely to match Terumo's licensing agreement,
we think this reaffirms
our investment thesis that there is significant value to be unlocked at Biosensors.
Reiterate BUY. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
allright
Senior |
30-Jul-2010 11:07
|
||||||
|
x 0
x 0 Alert Admin |
compare the 2 headlines. YET DBS had 2Q loss of $300m whilst BIG had net profit of us $3.24m
|
||||||
| Useful To Me Not Useful To Me | |||||||
|
AK_Francis
Supreme |
30-Jul-2010 10:21
Yells: "Happy go lucky, cheers." |
||||||
|
x 0
x 0 Alert Admin |
Wrong thread, but just for sharing.
|
||||||
| Useful To Me Not Useful To Me | |||||||
|
investor
Senior |
30-Jul-2010 10:19
|
||||||
|
x 0
x 0 Alert Admin |
Just read in Nomura's report today, that Biosensor's Licensee, Devax has got the CE Mark for their drug eluting stent for bifurcation lesions. As Devax is a small company, and if they cannot mkt or manufacture their own DES, this is where Biosensor's mkting and manufacturing structure comes in .(That is what the CEO mean by new technologies leveraging on the infrastructure of Biosensors). However, please note that IT IS NOT the case at the moment, ie this is only conjecture on my part - Devax has not yet approach Biosensors on the above. Biosensors will be entitiled to royalties from the sale of Devax's DES, just like Terumo's sales. For info. Not a call to buy/sell. |
||||||
| Useful To Me Not Useful To Me | |||||||
|
gbleng
Member |
30-Jul-2010 10:11
|
||||||
|
x 0
x 0 Alert Admin |
just read headlines for DBS result :DBS Group records Q2 net earnings of S$718m, highest in its history Posted: 30 July 2010 0806 hrs . No mention of $1bn charge in the headline news... see what i mean about selective reporting... |
||||||
| Useful To Me Not Useful To Me | |||||||
|
gbleng
Member |
29-Jul-2010 16:41
|
||||||
|
x 0
x 0 Alert Admin |
He also mentioned the upcoming TCT in US in Sept where they will be presenting the 12 month clinical results for Bio Freedom.... could be a catalyst because I think he said this will be the new stent technology that will spearhead biosensors entry into the US market. | ||||||
| Useful To Me Not Useful To Me | |||||||
